Skip to main content

Eli Lilly

Eli Lilly and Company is a global pharmaceutical enterprise involved in the research, clinical development, manufacturing, and marketing of human healthcare products. The company's therapeutic core spans endocrinology, oncology, immunology, and neuroscience. Principal revenue drivers consist of key proprietary medicines, notably tirzepatide formulations sold under the brand names Mounjaro and Zepbound, alongside oncology and immunology treatments like Verzenio and Taltz. Its end markets encompass healthcare systems, retail pharmacy networks, government purchasers, and patients globally. Eli Lilly holds a market-leading international position in diabetes and metabolic health treatments. Headquartered in Indianapolis, Indiana, the company's common stock trades publicly on the New York Stock Exchange.

199 of the funds FundTelligence covers report a position in Eli Lilly.

Legal name
Eli Lilly & Co
Sector
Health Care
Country
United States
Funds holding it
199
Exposure themes
Incretin & GLP-1 Therapies, Multiple, Obesity, Obesity & Metabolic Health, Treatment, Women's Health

Funds holding Eli Lilly

Showing the 8 largest of 199 funds holding it.

Loading...